Aiforia Technologies (AIFORIA) Q4 2024 earnings summary

Executive summary

• Order book increased 118% year-over-year, driven by a strategic focus on the clinical market and demand for AI-assisted image analysis, with clinical revenue now comprising 50% of total revenue.

• Major clinical deals and multi-year partnerships were closed in Europe, North America, and Asia, including Mayo Clinic, NHS, Memorial Hospital Istanbul, Fimlab (Finland), AP-HP (France), Castile and León (Spain), Lombardy (Italy), and Memorial Hospitals Group (Turkey).

• Product portfolio expanded with new CE-IVD and IVDR-regulated AI models, including a Mayo Clinic collaboration for colorectal cancer recurrence prediction and the launch of AiforiaⓇ Studies for preclinical research.

• Strong partnerships and integrations with major scanner, cloud, and LIS vendors support scalability and interoperability.

• Shift from smaller deals to multi-year contracts with large hospital districts, reflecting a stable and growing market position.

Financial highlights

• Revenue increased by 19% year-over-year to EUR 2.85 million.

• Order book grew 118% year-over-year, reaching nearly EUR 5.2 million, mainly from clinical contracts.

• EBITDA improved to EUR -8,220 thousand from EUR -9,699 thousand year-over-year.

• Cash and cash equivalents at year-end were EUR 11.5 million.

• Product development investment totaled EUR 5,581 thousand.

Outlook and guidance

• Short-term targets include expanding clinical and pre-clinical offerings, forming at least three new strategic partnerships, achieving 15 key accounts, and reaching positive operating cash flow.

• Mid-term goals: profitable business by 2027, revenue over EUR 100 million, and 50 key accounts by 2030.

• Continued investment in R&D and regulatory approvals to maintain product edge and market leadership.

• Positive market outlook with growing demand for digital pathology and AI-driven solutions, especially in Europe.